Navigation Links
Adventrx To Develop ANX-188 For Complications Of Arterial Disease
Date:2/28/2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced its plans to develop ANX-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease.  Peripheral arterial disease affects an estimated 8 to 12 million people in the United States.

Arterial disease resulting from atherosclerotic and thromboembolic processes is a common circulatory problem in which plaque-obstructed arteries reduce the flow of blood to tissues.  Peripheral arterial disease refers to disease affecting arteries outside the brain and heart and often refers to blockage of arteries in the lower extremities.  Ischemic cerebrovascular infarction, or stroke, results from blockage of arteries to the brain, while myocardial infarction, or heart attack, results from blockage of arteries to the heart.  Thrombolytic agents, such as tPA (tissue plasminogen activator), commonly referred to as "clot busting" drugs, are used to treat acute complications of peripheral arterial disease, heart attack and stroke. 

R. Martin Emanuele , Senior Vice President, Development, said: "Data from experimental models demonstrate the potential for ANX-188, when used alone or in combination with thrombolytics, to improve outcomes for patients with thrombotic arterial disease, whether manifesting as acute limb ischemia, stroke or some other variant.  Studies in animals and humans suggest that ANX-188 can shorten time-to-thrombolysis, improve blood flow, delay re-occlusion and reduce reperfusion injury, each of which may improve the effectiveness of existing thrombolytic agents." 

Santosh Vetticaden, Chief Medical Officer, said: "We plan to evaluate the potential of ANX-188 in arterial disease initially by evaluating it in acute limb ischemia.&#
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
2. ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4
3. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
4. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
5. ADVENTRX Reports Third Quarter 2012 Financial Results
6. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
7. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
8. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
9. ADVENTRX Announces Appointment Of Chief Medical Officer
10. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
11. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" ... analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... Vials, and IV solutions), Solid Dosage Forms (Tablets and ... Gels, Creams & Ointments). The report provides ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices. , ... , , ... ... ...
... , ATLANTA , March 22 Fulcrum Ventures announced today that they invested $1.25 ... solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia , ... ... , ...
Cached Medicine Technology:EmSense Announces Release of Revolutionary EmBand 24(TM) 2EmSense Announces Release of Revolutionary EmBand 24(TM) 3EmSense Announces Release of Revolutionary EmBand 24(TM) 4Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 2Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 3
(Date:8/20/2014)... Rockville Centre, NY (PRWEB) August 20, 2014 ... Martinotti and filed on August 7 in the multicounty ... New Jersey (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; ... in the MCL have been dismissed without prejudice. The ... “in the process of being resolved.” The Rottenstein Law ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... One Call Alert expands its line of personal ... fully-mobile wearable device that connects customers to the help they ... a day, 365 days a year. , ResCube can go ... operates on the T-Mobile nationwide network like a cell phone, ... , Like with the other One Call Alert systems, ResCube ...
(Date:8/20/2014)... Auckland suggest that both major forms of diabetes are the ... today in the FASEB Journal (20 August), provide ... are both caused by the formation of toxic clumps of ... on 20 years, work in New Zealand, suggest that type-1 ... reversed by medicines that stop amylin forming these toxic clumps. ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... May 21, 2012. West Orange, NJ. Scientists at ... studies in multiple sclerosis at the Hilton San Diego ... John DeLuca, Nancy Chiaravalloti and Yael Goverover are addressing ... Multiple Sclerosis Centers (CMSC) and the Americas Committee for ...
... peers and primary care office staff can help patients improve ... new drug, a new study found. Barbara J. Turner, M.D., ... senior author. The randomized, controlled trial examined whether six ... care office staff could benefit African-American patients who had ...
... 21 (HealthDay News) -- Heart damage can be present in obese ... preliminary study found. Obesity is a risk factor for heart ... to their hearts. In the new study, researchers examined the ... overweight and 32 obese -- with no symptoms of heart disease. ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... Almost a century after telephone pioneer Alexander Graham ... vapor sensors ― "electronic noses" ― are being developed ... and other futuristic uses. A new episode in ... series takes viewers on a behind-the-science tour of ...
Cached Medicine News:Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2